Agenus Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
30,072.70
42,486.20
87,881.10
126,995.20
120,692.50
162,044
Depreciation, Depletion & Amortization
586.30
1,584.00
1,957.60
4,947.80
6,006.30
6,288
Other Funds
53.30
56,353.10
28,180.00
5,000.00
-
24,491.40
Funds from Operations
22,093.70
32,227.50
53,801.40
90,360.90
87,746.20
131,264.60
Changes in Working Capital
2,560.80
6,007.10
6,626.00
10,400.00
6,479.00
170.10
Net Operating Cash Flow
19,532.90
38,234.60
47,175.40
79,960.80
94,225.10
131,094.50
Capital Expenditures
813.50
2,819.80
3,591.30
12,519.70
3,120.40
Sale of Fixed Assets & Businesses
-
514.50
-
-
120.00
Purchase/Sale of Investments
450.00
14,507.80
20,458.60
30,115.90
5,064.00
Net Investing Cash Flow
363.50
16,813.10
31,232.00
17,596.20
2,063.60
Cash Dividends Paid - Total
-
461.00
-
-
-
Issuance/Reduction of Debt, Net
733.40
3,333.30
106,114.60
144.70
14,519.30
Net Financing Cash Flow
25,780.20
52,810.70
189,579.70
2,461.00
80,538.20
Net Change in Cash
5,883.70
1,637.50
110,988.40
65,254.90
11,261.40
Free Cash Flow
20,346.50
41,054.40
50,766.80
92,480.60
97,345.50
Deferred Taxes & Investment Tax Credit
-
-
5,387.10
-
-
-
Net Assets from Acquisitions
-
-
7,182.10
-
-
Change in Capital Stock
26,566.80
251.90
111,645.10
2,683.60
66,019.00
Exchange Rate Effect
-
599.50
183.90
429.20
361.90

About Agenus

View Profile
Address
3 Forbes Road
Lexington Massachusetts 02421
United States
Employees -
Website http://www.agenusbio.com
Updated 07/08/2019
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, Next-gen CTLA-A, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H.